BALB/c mice bearing a transgenic IL-12 receptor β2 gene exhibit a nonhealing phenotype to Leishmania major infection despite intact IL-12 signaling

被引:30
|
作者
Nishikomori, R
Gurunathan, S
Nishikomori, K
Strober, W
机构
[1] NIAID, Mucosal Immun Sect, Lab Clin Invest, NIH, Bethesda, MD 20892 USA
[2] NIAID, Clin Immunol Sect, Lab Clin Invest, NIH, Bethesda, MD 20892 USA
来源
JOURNAL OF IMMUNOLOGY | 2001年 / 166卷 / 11期
关键词
D O I
10.4049/jimmunol.166.11.6776
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
In BALB/c mice infected with Leishmania major, early secretion of IL-4 leads to a Th2-type response and nonhealing. We explored the role of IL-4-induced down -regulation of the IL-12R beta2 chain in the establishment of this Th2 response. First, we showed that the draining lymph nodes of resistant C57BL/6 mice infected with L. major were enriched in CD4(+)/IL-12R beta2 chain' cells producing IFN-gamma. Next, we demonstrated that BALB/c background mice bearing an IL-12R beta2-chain transgene manifested a nonhealing phenotype similar to wild-type littermates despite the persistence of their ability to undergo STAT4 activation. Finally, we found that such transgenic mice display more severe infection than wild-type littermates when treated with IL-12 7 days after infection, and under this condition, the mice display increased Leishmania Ag-Induced IL-4 secretion. These studies indicate that although CD4(+)/IL-12R beta2 chain' T cells are important components of the Th1 response, maintenance of 1L-12R beta2 chain expression is not sufficient to change a Th2 response to a Th1 response in vivo and thus to allow BALB/c mice to heal L major infection. The Journal of Immunology, 2001, 166: 6776-6783.
引用
收藏
页码:6776 / 6783
页数:8
相关论文
共 50 条
  • [21] Induction of host resistance to Leishmania major by IL-12 and IL-18: In vivo IL-12 treatment up-regulates IL-18 receptor expression on T cells.
    Yoshimoto, T
    Ohkusu, K
    Okamura, H
    Nakanishi, K
    FASEB JOURNAL, 1998, 12 (05): : A1068 - A1068
  • [22] IL-2 limits IL-12 enhanced lymphocyte proliferation during Leishmania amazonensis infection
    Ramer-Tait, Amanda E.
    Petersen, Christine A.
    Jones, Douglas E.
    CELLULAR IMMUNOLOGY, 2011, 270 (01) : 32 - 39
  • [23] IL-12 is required to maintain a Th1 response during Leishmania major infection
    Park, AY
    Hondowicz, BD
    Scott, P
    FASEB JOURNAL, 2000, 14 (06): : A1182 - A1182
  • [24] IL-12 is required to maintain a Th1 response during Leishmania major infection
    Park, AY
    Hondowicz, BD
    Scott, P
    JOURNAL OF IMMUNOLOGY, 2000, 165 (02): : 896 - 902
  • [25] Restoration of IL-12 signaling pathway in IL-12 receptor beta-1 (IL-12Rβ1) KO mice after retroviral-mediated gene transfer into hematopoietic stem cells
    Bosticardo, M
    Novelli, F
    Casanova, JL
    Candotti, F
    FASEB JOURNAL, 2004, 18 (04): : A47 - A47
  • [26] Mutations of the IL-12 receptor β2 chain gene in atopic subjects
    Matsui, E
    Kaneko, H
    Fukao, T
    Teramoto, T
    Inoue, R
    Watanabe, M
    Kasahara, K
    Kondo, N
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1999, 266 (02) : 551 - 555
  • [27] Early production of IL-4 in susceptible mice infected with Leishmania major rapidly induces IL-12 unresponsiveness
    Launois, P
    Swihart, KG
    Milon, G
    Louis, JA
    JOURNAL OF IMMUNOLOGY, 1997, 158 (07): : 3317 - 3324
  • [28] IL-12 mediated prevention of spontaneous tumors in C-Neu transgenic inbred BALB/c and FVB mice.
    Fornl, G
    Boggio, K
    Nicoletti, G
    Di Carlo, E
    Colombo, MP
    Wolf, S
    Musiani, P
    FASEB JOURNAL, 1998, 12 (04): : A288 - A288
  • [29] IL-12 signaling pathway is restored in IL-12 receptor beta-1 (IL-12Rβ1) KO mice after retroviral-mediated gene transfer into hematopoietic stem cells.
    Bosticardo, M
    Novelli, F
    Casanova, JL
    Candotti, F
    BLOOD, 2003, 102 (11) : 492A - 492A
  • [30] Reconstitution of the IL-12 signaling pathway in IL-12 receptor beta-1 (IL-12Rβ1) KO mice upon transplantation of retrovirally transduced hematopoietic stem cells
    Bosticardo, M
    Novelli, F
    Casanova, JL
    Candotti, F
    MOLECULAR THERAPY, 2003, 7 (05) : S409 - S409